RM-NBS / Neurobehavioural and neuroendocrine signalling
PE-22-28
Also known as: PE 22-28 · Spadin analog PE-22-28
Grade describes the published research on the molecule. It is not a quality score, a safety score, or a release state.
What this is
PE-22-28 is a shortened analog derived from spadin research. Terminal modifications can preserve or remove activity, so the exact sequence and modification state are part of the evidence match.
Evidence position
Cellular and mouse research supports Grade C. The record does not include a validated human outcome.
What the record does not establish
Preclinical findings do not establish effects in people or authenticate a supplier’s spray, vial or lot.
Sources
- 01Shortened spadin analogs display TREK-1 inhibition and preclinical activityPubMed
- Shows
- Cellular channel assays and mouse behavioral-model findings for PE-22-28 and related analogs
- Does not show
- Preclinical models; multiple analogs and modifications require exact identity matching
External database index
LIVE DATABASE INDEX / SEPARATE FROM CURATED EVIDENCE
Records below come directly from public scientific databases. They help find relevant material, but do not affect the evidence grade until they are matched to the molecule and added to the curated source list.
PUBMED / FOUND RECORDS
- Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity.Frontiers in pharmacology / 2017PMID 28955242 / DOI 10.3389/fphar.2017.00643